Advisors Preferred’s Myriad Genetics MYGN Stock Holding History

Advisors Preferred’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,259	Closed	-$359K	–	212
2021 Q3	$359K	Buy	+11,259	New	+$374K	0.05%	117
2017 Q3	–	Sell	-1,829	Closed	-$47K	–	264
2017 Q2	$47K	Buy	+1,829	New	+$38.8K	0.03%	145

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Advisors Preferred's MYGN Position: Q4 2021 in Review

Advisors Preferred sold out of Myriad Genetics (MYGN) in Q4 2021, closing a stake of 11,259 shares — an estimated $359K sold.

Advisors Preferred first reported a position in MYGN in Q2 2017 and held it in 2 quarters. The position peaked at $359K in Q3 2021. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2021.

Advisors Preferred reported no remaining Myriad Genetics position as of Q4 2021 after selling out during the quarter.
Advisors Preferred sold 11,259 Myriad Genetics shares in Q4 2021, an estimated $359K.
Advisors Preferred first reported a position in Myriad Genetics in Q2 2017 and held it in 2 quarters.
Advisors Preferred's Myriad Genetics position peaked at $359K in Q3 2021.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2021.

Based on Advisors Preferred's 13F filing for Q4 2021, filed 7 Feb 2022.